Abstract
Neurotraumatic and neurodegenerative diseases are mediated by synergistic action of excitotoxicity, oxidative stress, neuroinflammation, and misfolding and deposition of specific proteins in the brain tissue (Fig. 10.1) (Farooqui, 2009a). Among neurotraumatic diseases, the onset of stroke may be modulated by age, genes, diet, and lifestyle. Spinal cord injury (SCI) and traumatic brain injury (TBI) are caused by mechanical insults to the spinal cord and brain tissues (Farooqui and Horrocks, 2007), whereas stroke is a metabolic insult induced by severe reduction or blockade in cerebral blood flow. In contrast, neurodegenerative diseases occur in familial and sporadic forms. Familial mutations play an important role in protein misfolding and aggregation, but the majority of cases of neurodegenerative diseases are sporadic, indicating that other factors namely age, diet, lifestyle may also contribute to the pathogenesis of neurodegenerative diseases (Farooqui and Horrocks, 2007).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bass SD, Chen WK, Mulkem RV, Bakshi R (2006) Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17:31–40
Block ML, Hong J-S (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77–98
Bray GA, Nielsen SJ, Popkin BM (2004) Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79:537–543
Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer’s disease in the United State and public health impact of delaying disease onset. Am J Public Health 88:1337–1342
Caroli A, Frisoni GB (2009) Quantitative evaluation of Alzheimer’s disease. Expert Rev Med Devices 6:569–588
Chen L, Wei Y, Wang X, He R (2009) D-Ribosylated Tau forms globular aggregates with high cytotoxicity. Cell Mol Life Sci 66:2559–2571
Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5(2):e9052
Cogan JF, Mitchell OS (2003) Perspective from the President’s commission on Social Security Reform. J Econ Perspect 7:149–172
Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 29:14770–14778
Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O‘Keefe JH, Brand-Miller J (2005) Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 81:341–354
Culmsee C, Landshamer S (2006) Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr Alzheimer Res 3:269–283
de Leon MJ, DeSante S, Zinkowski R, Kerkman D, DeBermadis J, Li J, Lair L, Reiberg B, Tsui W, Rusinnek H (2004) MRI and CSF studies in the early diagnosis of Alzheimer’s disease. J Intern Med 256:205–223
Eaton SB (2006) The ancestral human diet: what was it and should it be a paradigm for contemporary nutrition? Proc Nutr Soc 65:1–6
Farooqui AA, Horrocks LA (2007) Glycerophospholipids in brain. Springer, New York, NY
Farooqui AA, Horrocks LA, Farooqui T (2007a) Modulation of inflammation in brain: a matter of fat. J Neurochem 101:577–599
Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T (2007b) Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Rev 56:443–471
Farooqui AA, Ong WY, Horrocks LA (2008) Neurochemical aspects of excitotoxicity. Springer, New York, NY
Farooqui T, Farooqui AA (2009) Aging: an important factor for the pathogenesis of neurodegenerative diseases. Mech Aging Dev 130:203–215
Farooqui AA (2009a) Hot topics in neural membrane lipidology. Springer, New York, NY
Farooqui AA (2009b) Beneficial effects of fish oil on human brain. Springer, New York, NY
Finch CE, Sapolsky RM (1999) The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol Aging 20:407–428
Fleming JJ, England PM (2010) AMPA receptors and synaptic plasticity: a chemist’s perspective. Nat Chem Biol 6:89–97
Gilgun-Sherki Y, Melamed E, Offen D (2006) Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharmaceut Des 12:3509–3519
Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. Nat Neurosci Rev 9:568–578
Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement 4:38–48
Handley OJ, Naji JJ, Dunnett SB, Rosser AE (2006) Pharmaceutical, cellular and genetic therapies for Huntington’s disease. Clin Sci (Lond) 110:73–88
Hayashi T, Shoji M, Abe K (2006) Molecular mechanisms of ischemic neuronal cell death–with relevance to Alzheimer’s disease. Curr Alzheimer Disease 3:351–358
Henley SM, Bates GP, Tabrizi SJ (2005) Biomarkers for neurodegenerative diseases. Curr Opin Neurol 18:698–705
Hodes RJ (2006) Public funding for Alzheimer’s disease research in United States. Nat Med 12:770–773
Jin H, Randazzo J, Zhang P, Kador PF (2010) Multifunctional antioxidants for the treatment of age-related diseases. J Med Chem 53:1117–1127
Kamphuis PJ, Wurtman RJ (2009) Nutrition and Alzheimer’s disease: pre-clinical concepts. Eur J Neurol 16(Suppl 1):12–18
Langstrom B, Andren PE, Lindhe O, Svedberg M, Hall H (2007) In vitro imaging techniques in neurodegenerative diseases. Mol Imaging Biol 9:161–175
Lu Y, Hong S, Gotlinger K, Serhan CN (2006) Lipid mediator informatics and proteomics in inflammation-resolution. Sci World J 6:589–614
Mattson MP, Duan W, Pedersen WA, Culmsee C (2001) Neurodegenerative disorders and ischemic brain diseases. Apoptosis 6:69–81
Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other neurodegenerative diseases. Neurobiol Aging 26:587–595
Miranda HV, Outerio TF (2009) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol Dec 31 [Epub ahead of print]
Molteni R, Bernard RJ, Ying Z, Roberts CK, Gomez-Pinilla F (2002) A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112:803–814
Naigai Y, Fujikake N, Popiel HA, Wada K (2010) Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol Fab 16 [Epub ahead of print]
Nile DY, Xu G, Ahmed S, Xiao ZC (2007) DNA vaccine and the CNS axonal regeneration. Curr Pharm Des 13:2500–2506
Ono M (2007) Molecular imaging of beta-amyloid plaques in the brain. Brain Nerve 59:233–240
Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768–773
Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ (1995) Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging 16:973–975
Revill P, Moral MA, Prous JR (2006) Impaired insulin signaling and the pathogenesis of Alzheimer’s disease. Drug Today 42:785–790
Schmitt HP (2006) epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis. Med Hypotheses 66:698–906
Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum. CNS Neurosci Ther 15:358–374
Simopoulos AP (2002) The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56:365–379
Simopoulos AP (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60:502–507
Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, Barrio JR (2008) Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 7:161–172
Stranahan RS, Normal ED, Lee K, Cutler RG, Telljohan RS, Egan JM, Mattson MP (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18:1085–1088
Takeuchi M, Yamagishi S, Iwaki M, Nakamura K, Imaizumi T (2004) Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases. Int J Clin Pharmacol 24:95–101
Tan DX, Manchester LC, Sainz R, Mayo JC, Alvares FL, Reiter RJ (2003) Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin Ther Patents 13:1513–1543
Thobois S, Guillouet S, Bronssolle E (2001) Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease. Neurophysiol Clin 31:321–340
Trojanowski JQ (2008) PENN neurodegenerative disease research – in the spirit of Benjamin Franklin. Neurosignals 16:5–10
Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73:294–301
Wang JY, Wen LL, Huang YN, Chen YT, Ku MC (2006) Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharmaceut Des 12:3521–3533
Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G (2006) Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med 84:635–646
Wood PL (1998) Neuroinflammation: mechanisms and management. Humana Press, Totowa, NJ
Wurtman RJ, Cancev W, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutri 29:59–87
Xie CW (2004) Calcium-regulated signaling pathways: role in amyloid β-induced synaptic dysfunction. Neuromolecular Med 6:53–64
Xu G, Nie DY, Chen JT, Wang CY, Yu FG, Sun L, Luo XG, Ahmed S, Xiao ZC (2004) Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration. J Neurochem 91:1018–1023
Yan SD, Bierhaus A, Nawroth PP, Stern DM (2009) RAGE and Alzheimer’s disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimer Res 16:833–843
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Farooqui, A.A. (2010). Perspective and Direction for Future Developments on Neurotraumatic and Neurodegenerative Diseases. In: Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6652-0_10
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6652-0_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6651-3
Online ISBN: 978-1-4419-6652-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)